Sandbox leucocytosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 458: Line 458:
{|
{|
|-
|-
! colspan="3" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Normal variant oral lesions
! colspan="4" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Surface Lesions of Oral Mucosa
!
!
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
Line 465: Line 467:
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|-
|-
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" rowspan="16" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Leukoedema
* White
| rowspan="11" |Epithelial
|Geographic tongue
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 473: Line 478:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
|Hairy tongue
* Fordyce granules
|
|
|
|
|
|
|-
|Leukoedema
|
|
|
|
|
|
|-
|White sponge nevus
|
|
|
|
|
|
|-
|Hairy leukoplakia
|
|
|
|
|
|
|-
|Lichen planus
|
|
|
|
|
|
|-
|Nicotinic stomatitis
|
|
|
|
|
|
|-
|Hyperkeratosis
|
|
|
|
|
|
|-
|Epithelial dysplasia
|
|
|
|
|
|
|-
|Carcinoma in-situ
|
|
|
|
|
|
|-
|Squamous cell carcinoma
|
|
|
|
|
|
|-
| rowspan="2" |Surface debris
|Candidiosis
|
|
|
|
|
|
|-
|Burn
|
|
|
|
|
|
|-
| rowspan="3" |Subepithelial
|Congenital keratotic cyst
|
|
|
|
|
|
|-
|Scar
|
|
|
|
|
|
|-
|Fordyce granules
|
|
|
|
|
|
|-
| colspan="3" rowspan="20" |
* Pigmented
| rowspan="11" |Localized
| rowspan="3" |Intravascular
|Hemangioma
|
|
|
|
|
|-
|Varix
|
|
|
|
|
|-
|Kaposi sarcoma
|
|
|
|
|
|-
| rowspan="3" |Extravasated blood
|Hematoma
|
|
|
|
|
|-
|Ecchymosis
|
|
|
|
|
|-
|Petechiae
|
|
|
|
|
|-
| rowspan="4" |Melanocytic
|Oral melanocytic macule
|
|
|
|
|
|-
|Nevus
|
|
|
|
|
|-
|Melanoma
|
|
|
|
|
|-
|Ephelis
|
|
|
|
|
|-
|Tattoo
|
|
|
|
|
|
|-
| rowspan="9" |Diffuse
|Hereditary
|
|
|
|
|
|
|-
|Addison's disease
|
|
|
|
|
|
|-
|Heavy metal ingestion
|
|
|
|
|
|
|-
|Peutz-Jeghers syndrome
|
|
|
|
|
|
|-
|Neurofibromatosis
|
|
|
|
|
|
|-
|Polyostotic fibrous dysplasia
|
|
|
|
|
|
|-
|Pregnancy
|
|
|
|
|
|
|-
|Medication
|
|
|
|
|
|
|-
|Smoker's melanosis
|
|
|
|
|
|
|-
| colspan="3" rowspan="18" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Vesicular/Ulcerative/Erythematous
|Hereditary
|Epidermolysis bullosa
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 480: Line 767:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
| rowspan="6" |Viral
|Herpes simplex
|
|
|
|
|
|
|-
|Herpangina
|
|
|
|
|
|
|-
|Hand foot and mouth disease
|
|
|
|
|
|
|-
|Herpes zoster
|
|
|
|
|
|
|-
|Infectious mononucleosis
|
|
|
|
|
|
|-
|Varicella
|
|
|
|
|
|
|-
| rowspan="5" |Autoimmune
|Erosive lichen planus
|
|
|
|
|
|
|-
|Mucous memrane pemphigoid
|
|
|
|
|
|
|-
|Pemphigous vulgaris
|
|
|
|
|
|
|-
|Bullous pemphigoid
|
|
|
|
|
|
|-
|Lupus erythmatosus
|
|
|
|
|
|
|-
| rowspan="5" |Idiopathic
|Aphthous ulcer
|
|
|
|
|
|
|-
|Erythema multiforme
|
|
|
|
|
|
|-
|Erythroplakia
|
|
|
|
|
|
|-
|Medication induced mucositis
|
|
|
|
|
|
|-
|Contact stomatitis
|
|
|
|
|
|
|-
|Mycotic
|Candidiosis
|
|
|
|
|
|
|-  
|-  
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign Oral lesions
! colspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign Oral lesions
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
Line 490: Line 918:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Pyogenic granuloma
* Pyogenic granuloma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 498: Line 929:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Peripheral ossifying fibroma
* Peripheral ossifying fibroma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 506: Line 940:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Granular cell tumor
* Granular cell tumor
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 514: Line 951:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Peripheral giant cell granuloma
* Peripheral giant cell granuloma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 522: Line 962:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral hemangioma
* Oral hemangioma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 532: Line 975:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Traumatic neuroma
* Traumatic neuroma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 540: Line 986:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Neurofibroma
* Neurofibroma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 548: Line 997:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Schwannoma
* Schwannoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 554: Line 1,006:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" rowspan="2" |
| colspan="2" rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Palisaded encapsulated neuroma
* Palisaded encapsulated neuroma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 562: Line 1,017:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 570: Line 1,028:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Neodymium-doped yttrium alluminium garnet  
* Neodymium-doped yttrium alluminium garnet  
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 578: Line 1,039:
| rowspan="11" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| rowspan="11" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Pigmented lesions
* Pigmented lesions
| rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Diffuse
* Diffuse
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Peutz-jeghers syndrome
* Peutz-jeghers syndrome
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 588: Line 1,052:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Addison's disease
* Addison's disease
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 596: Line 1,063:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Heavy metal
* Heavy metal
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 604: Line 1,074:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Drug induced
* Drug induced
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 612: Line 1,085:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Post inflammatory
* Post inflammatory
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 620: Line 1,096:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Smoker's melanosis
* Smoker's melanosis
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 630: Line 1,109:
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Focal
* Focal
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Ephelides
* Ephelides
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 638: Line 1,120:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Labial melanocytic macules
* Labial melanocytic macules
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 646: Line 1,131:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Amalgam tattoo
* Amalgam tattoo
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 654: Line 1,142:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral melanoacanthoma
* Oral melanoacanthoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 662: Line 1,153:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral melanocytic nevi
* Oral melanocytic nevi
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 671: Line 1,165:
|-  
|-  
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pre-malignant oral lesions
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pre-malignant oral lesions
!
!
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
Line 679: Line 1,176:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Leukoplakia
* Leukoplakia
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 687: Line 1,187:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral proliferative verrucous leukoplakia
* Oral proliferative verrucous leukoplakia
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 695: Line 1,198:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Erythroplakia
* Erythroplakia
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 703: Line 1,209:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral submucus fibrosis
* Oral submucus fibrosis
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 711: Line 1,220:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral lichen planus and lichenoid lesions
* Oral lichen planus and lichenoid lesions
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 719: Line 1,231:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral discoid lupus erythmatosus
* Oral discoid lupus erythmatosus
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 727: Line 1,242:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral chronic graft vs host disease
* Oral chronic graft vs host disease
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 735: Line 1,253:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Actinic chelitis
* Actinic chelitis
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 742: Line 1,263:
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant oral lesions
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant oral lesions
!
!
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
Line 752: Line 1,276:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Squamous cell carcinoma
* Squamous cell carcinoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 760: Line 1,287:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Basal cell carcinoma
* Basal cell carcinoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 768: Line 1,298:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Verrucous crcinoma
* Verrucous crcinoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 776: Line 1,309:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Spindle cell carcinoma
* Spindle cell carcinoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 784: Line 1,320:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Adenoid squamous cell carcinoma
* Adenoid squamous cell carcinoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 792: Line 1,331:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Lymphoepithelioma and transitional cell carcinoma
* Lymphoepithelioma and transitional cell carcinoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 800: Line 1,342:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Malignant melanoma
* Malignant melanoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 810: Line 1,355:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Malignant schwannoma
* Malignant schwannoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 820: Line 1,368:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Leiomyosarcoma
* Leiomyosarcoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 828: Line 1,379:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Rhabdomyosarcoma
* Rhabdomyosarcoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 838: Line 1,392:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Malignant lymphoma
* Malignant lymphoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 846: Line 1,403:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Non Hodgkin lymphoma
* Non Hodgkin lymphoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 854: Line 1,414:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Hodgkin lymphoma
* Hodgkin lymphoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 862: Line 1,425:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
*Burkitt's lymphoma
*Burkitt's lymphoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 870: Line 1,436:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Reticular cell sarcoma
* Reticular cell sarcoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 878: Line 1,447:
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Plasma cell tumor
* Plasma cell tumor
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Multiple myeloma
* Multiple myeloma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 886: Line 1,458:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: left;"|
| style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Plasmacytoma
* Plasmacytoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 898: Line 1,473:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Fibrosarcoma
* Fibrosarcoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 906: Line 1,484:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Liposarcoma
* Liposarcoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 916: Line 1,497:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Granular cell myoblastoma
* Granular cell myoblastoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 924: Line 1,508:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Congenital epulis
* Congenital epulis
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 932: Line 1,519:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Alveolar soft part sarcoma
* Alveolar soft part sarcoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 940: Line 1,530:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Melanocytic neuroectodermal tumor of infancy
* Melanocytic neuroectodermal tumor of infancy
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 948: Line 1,541:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Kaposi sarcoma
* Kaposi sarcoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 956: Line 1,552:
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Ewing's sarcoma
* Ewing's sarcoma
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 963: Line 1,562:
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infections
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infections
!
!
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
Line 971: Line 1,573:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Herpes simplex virus
* Herpes simplex virus
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 979: Line 1,584:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Varicella zoster virus
* Varicella zoster virus
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 987: Line 1,595:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Coxsackie virus
* Coxsackie virus
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 995: Line 1,606:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* HIV infection
* HIV infection
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,003: Line 1,617:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Syphilis  
* Syphilis  
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,011: Line 1,628:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Other infections
* Other infections
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,018: Line 1,638:
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autoimmune Conditions
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autoimmune Conditions
!
!
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
Line 1,026: Line 1,649:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Oral erosive lichen planus
* Oral erosive lichen planus
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,034: Line 1,660:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Systemic lupus erythamtosus
* Systemic lupus erythamtosus
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,042: Line 1,671:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Mucus membrane pemphigoid
* Mucus membrane pemphigoid
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,050: Line 1,682:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Bullous pemphigoid
* Bullous pemphigoid
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,058: Line 1,693:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Pemphigus vulgaris
* Pemphigus vulgaris
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,066: Line 1,704:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Paraneoplastic pemphigus
* Paraneoplastic pemphigus
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,074: Line 1,715:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Epidermolysis bullosa acquisita
* Epidermolysis bullosa acquisita
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,081: Line 1,725:
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Miscellaneous
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Miscellaneous
!
!
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
Line 1,089: Line 1,736:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Burning mouth syndrome
* Burning mouth syndrome
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,097: Line 1,747:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Contact stomatitis
* Contact stomatitis
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,105: Line 1,758:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Cheilitis
* Cheilitis
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,113: Line 1,769:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Mucoceles
* Mucoceles
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,121: Line 1,780:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Torus
* Torus
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,129: Line 1,791:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Dental erosions/Gingival overgrowth
* Dental erosions/Gingival overgrowth
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,137: Line 1,802:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Telangiectasias
* Telangiectasias
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,144: Line 1,812:
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: left;" |Tongue lesions
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: left;" |Tongue lesions
!
!
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features
Line 1,152: Line 1,823:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Atrophic glossitis
* Atrophic glossitis
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,160: Line 1,834:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Fissured tongue
* Fissured tongue
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,168: Line 1,845:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Black tongue
* Black tongue
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,176: Line 1,856:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Black hairy tongue
* Black hairy tongue
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,184: Line 1,867:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Pigmented fungiform papillae of the tongue
* Pigmented fungiform papillae of the tongue
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,192: Line 1,878:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Geographic tongue
* Geographic tongue
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 1,200: Line 1,889:
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" |
* Median rhomboid glossitis
* Median rhomboid glossitis
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 05:48, 24 January 2019


Disease Presentation Risk Factors Diagnosis Affected Organ Systems Important features Picture
Diseases predominantly affecting the oral cavity
Oral Candidiasis
  • Denture users
  • As a side effect of medication, most commonly having taken antibiotics. Inhaled corticosteroids for the treatment of lung conditions (e.g, asthma or COPD) may also result in oral candidiasis which may be reduced by regularly rinsing the mouth with water after taking the medication.
  • Clinical diagnosis
  • Confirmatory tests rarely needed
Localized candidiasis

Invasive candidasis

Tongue infected with oral candidiasis - By James Heilman, MD - Own work, CC BY-SA 3.0, httpscommons.wikimedia.orgwindex.phpcurid=11717223.jpg
Herpes simplex oral lesions
  • Stress
  • Recent URTI
  • Female sex
  • The symptoms of primary HSV infection generally resolve within two weeks
Oral herpes simplex infection - By James Heilman, MD - Own work, CC BY-SA 3.0, httpscommons.wikimedia.orgwindex.phpcurid=19051042.jpg
Aphthous ulcers
  • Painful, red spot or bump that develops into an open ulcer
  • Physical examination
  • Diagnosis of exclusion
  • Oral cavity
  • Self-limiting , Pain decreases in 7 to 10 days, with complete healing in 1 to 3 weeks
By Ebarruda - Own work, CC BY-SA 3.0, httpscommons.wikimedia.orgwindex.phpcurid=7903358
Squamous cell carcinoma
Squamous cell carcinoma - By Luca Pastore, Maria Luisa Fiorella, Raffaele Fiorella, Lorenzo Lo Muzio - http://www.plosmedicine.org/article/showImageLarge.action?uri=info%3Adoi%2F10.1371%2Fjournal.pmed.0050212.g001, CC BY 2.5, https://commons.wikimedia.org/w/index.php?curid=15252632
Leukoplakia
  • Vulvar lesions occur independent of oral lesions
Leukoplakia - By Aitor III - Own work, Public Domain, https://commons.wikimedia.org/w/index.php?curid=9873087
Melanoma
Oral melanoma - By Emmanouil K Symvoulakis, Dionysios E Kyrmizakis, Emmanouil I Drivas, Anastassios V Koutsopoulos, Stylianos G Malandrakis, Charalambos E Skoulakis and John G Bizakis - Symvoulakis et al. Head & Face Medicine 2006 2:7 doi:10.1186/1746-160X-2-7 (Open Access), [1], CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=9839811
Fordyce spots
Fordyce spots - Por Perene - Obra do próprio, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=19772899
Burning mouth syndrome
Torus palatinus
Torus palatinus - By Photo taken by dozenist, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=846591
Diseases involving oral cavity and other organ systems
Behcet's disease
Behcet's disease - By Ahmet Altiner MD, Rajni Mandal MD - http://dermatology.cdlib.org/1611/articles/18_2009-10-20/2.jpg, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=17863021
Crohn's disease
Agranulocytosis
Syphilis
oral syphilis - By CDC/Susan Lindsley - http://phil.cdc.gov/phil_images/20021114/34/PHIL_2385_lores.jpg, Public Domain, https://commons.wikimedia.org/w/index.php?curid=2134349
Coxsackie virus
  • Symptomatic treatment
Hand-foot-and-mouth disease - adapted from atlasdermatologico.com
Chicken pox
Chickenpox - By James Heilman, MD - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=52872565
Measles
  • Unvaccinated individuals
  • Crowded and/or unsanitary conditions
  • Traveling to less developed and developing countries
  • Immunocompromized
  • Winter and spring seasons
  • Born after 1956 and never fully vaccinated
  • Health care workers
Koplick spots (Measles) - By CDC - http://phil.cdc.gov/PHIL_Images/20040908/4f54ee8f0e5f49f58aaa30c1bc6413ba/6111_lores.jpg, Public Domain, https://commons.wikimedia.org/w/index.php?curid=824483
Surface Lesions of Oral Mucosa Localization Differentiating features Diagnostic procedure Treatment
  • White
Epithelial Geographic tongue
Hairy tongue
Leukoedema
White sponge nevus
Hairy leukoplakia
Lichen planus
Nicotinic stomatitis
Hyperkeratosis
Epithelial dysplasia
Carcinoma in-situ
Squamous cell carcinoma
Surface debris Candidiosis
Burn
Subepithelial Congenital keratotic cyst
Scar
Fordyce granules
  • Pigmented
Localized Intravascular Hemangioma
Varix
Kaposi sarcoma
Extravasated blood Hematoma
Ecchymosis
Petechiae
Melanocytic Oral melanocytic macule
Nevus
Melanoma
Ephelis
Tattoo
Diffuse Hereditary
Addison's disease
Heavy metal ingestion
Peutz-Jeghers syndrome
Neurofibromatosis
Polyostotic fibrous dysplasia
Pregnancy
Medication
Smoker's melanosis
  • Vesicular/Ulcerative/Erythematous
Hereditary Epidermolysis bullosa
Viral Herpes simplex
Herpangina
Hand foot and mouth disease
Herpes zoster
Infectious mononucleosis
Varicella
Autoimmune Erosive lichen planus
Mucous memrane pemphigoid
Pemphigous vulgaris
Bullous pemphigoid
Lupus erythmatosus
Idiopathic Aphthous ulcer
Erythema multiforme
Erythroplakia
Medication induced mucositis
Contact stomatitis
Mycotic Candidiosis
Benign Oral lesions Localization Differentiating features Diagnostic procedure Treatment
  • Pyogenic granuloma
  • Peripheral ossifying fibroma
  • Granular cell tumor
  • Peripheral giant cell granuloma
  • Oral hemangioma
  • Benign peripheral nerve sheath tumor
  • Traumatic neuroma
  • Neurofibroma
  • Schwannoma
  • Palisaded encapsulated neuroma
  • Neodymium-doped yttrium alluminium garnet
  • Pigmented lesions
  • Diffuse
  • Peutz-jeghers syndrome
  • Addison's disease
  • Heavy metal
  • Drug induced
  • Post inflammatory
  • Smoker's melanosis
  • Focal
  • Ephelides
  • Labial melanocytic macules
  • Amalgam tattoo
  • Oral melanoacanthoma
  • Oral melanocytic nevi
Pre-malignant oral lesions Localization Differentiating features Diagnostic procedure Treatment
  • Leukoplakia
  • Oral proliferative verrucous leukoplakia
  • Erythroplakia
  • Oral submucus fibrosis
  • Oral lichen planus and lichenoid lesions
  • Oral discoid lupus erythmatosus
  • Oral chronic graft vs host disease
  • Actinic chelitis
Malignant oral lesions Localization Differentiating features Diagnostic procedure Treatment
  • Epithelial tissue origin
  • Squamous cell carcinoma
  • Basal cell carcinoma
  • Verrucous crcinoma
  • Spindle cell carcinoma
  • Adenoid squamous cell carcinoma
  • Lymphoepithelioma and transitional cell carcinoma
  • Malignant melanoma
  • Nerve tissue origin
  • Malignant schwannoma
  • Muscle tissue origin
  • Leiomyosarcoma
  • Rhabdomyosarcoma
  • Lymphoid tissue origin
  • Malignant lymphoma
  • Non Hodgkin lymphoma
  • Hodgkin lymphoma
  • Burkitt's lymphoma
  • Reticular cell sarcoma
  • Plasma cell tumor
  • Multiple myeloma
  • Plasmacytoma
  • Connective and Adipose tissue origin
  • Fibrosarcoma
  • Liposarcoma
  • Tumors of disputed origin
  • Granular cell myoblastoma
  • Congenital epulis
  • Alveolar soft part sarcoma
  • Melanocytic neuroectodermal tumor of infancy
  • Kaposi sarcoma
  • Ewing's sarcoma
Infections Localization Differentiating features Diagnostic procedure Treatment
  • Herpes simplex virus
  • Varicella zoster virus
  • Coxsackie virus
  • HIV infection
  • Syphilis
  • Other infections
Autoimmune Conditions Localization Differentiating features Diagnostic procedure Treatment
  • Oral erosive lichen planus
  • Systemic lupus erythamtosus
  • Mucus membrane pemphigoid
  • Bullous pemphigoid
  • Pemphigus vulgaris
  • Paraneoplastic pemphigus
  • Epidermolysis bullosa acquisita
Miscellaneous Localization Differentiating features Diagnostic procedure Treatment
  • Burning mouth syndrome
  • Contact stomatitis
  • Cheilitis
  • Mucoceles
  • Torus
  • Dental erosions/Gingival overgrowth
  • Telangiectasias
Tongue lesions Localization Differentiating features Diagnostic procedure Treatment
  • Atrophic glossitis
  • Fissured tongue
  • Black tongue
  • Black hairy tongue
  • Pigmented fungiform papillae of the tongue
  • Geographic tongue
  • Median rhomboid glossitis
Type of cancer Subtype Epidemiology Localization Clinical features Diagnostic procedures
Squamous cell carcinoma
  • Basaloid squamous cell carcinoma
  • Papillary squamous cell carcinoma
  • Spindle cell carcinoma
  • Acantholytic squamous cell carcinoma
  • Adenosquamous carcinoma
Verrucous carcinoma
  • Older males
  • 5th and 6th decades of life
  • Males are affected more often than females
  • Hard palate
  • Anterior two-thirds of the tongue, including dorsal, ventral and lateral surfaces, and the floor of mouth
  • Often asymptomatic or may present with vague symptoms and minimal physical finding
Biopsy shows:

Thickened club-shaped

papillae and blunt stromal invaginations

of well-differentiated squamous epithelium with marked keratinization

Lymphoepithelial carcinoma 0.8-2% of all oral or oropharyngeal cancers
  • Some tumors can be bilateral
Biopsy chows:
Epithelial precursor lesions --- --- Seen in the entire digestive tract Biopsy shows:
Proliferative verrucous leukoplakia and precancerous conditions ---
  • Average age at diagnosis is 62 years
  • Women are more commonly afflicted (ratio, 4:1)
An aggressive form of oral leukoplakia with considerable morbidity and

strong predilection to malignant transformation

Biopsy shows:
Papillomas Squamous cell papilloma and

verruca vulgaris

  • Common in children and in adults in the 3rd to 5th decades
  • Almost equal sex incidence with a slight male predominance
Any oral site may be affected mostly: Soft, pedunculated lesions formed by a cluster of finger-like fronds or a sessile, dome-shaped lesion with a nodular, papillary or verrucous surface Biopsy shows:
Condyloma acuminatum 2nd and 5th decade with a peak in teenagers and young adults
  • Painless, rounded, dome-shaped exophytic nodules
  • 15 mm in diameter
  • Have a broad base and a nodular or mulberry-like surface that is slightly red, pink or of normal mucosal color.
  • Lesions may be multiple and are then usually clustered
Biopsy shows:

Several sessile, cauliflower-like swellings forming a cluster

Focal epithelial hyperplasia Disease of children, adolescents and young adults
  • Soft rounded or flat plaque-like sessile swelling.
  • Usually pink or white in color
  • 2-10mm in diameter
Biopsy shows:
  • Rounded sessile swelling formed by a sharply demarcated zone of epithelial acanthosis
  • Koilocytes similar to those of squamous papilloma are usually present
Granular cell tumor ---
  • Arise in all age groups, with a peak between 40 and 60 years
  • Females are affected more often than males with an M/F ratio of 2:1
  • The overlying epithelium is of normal color or may be slightly pale
Biopsy shows:
Keratoacanthoma ---
  • Occurs more often in

whites

  • Twice as frequent in

men as in women

Biopsy shows:
Papillary hyperplasia --- Affects all age groups Palate Asymptomatic nodular or papillary mucosal lesion Biopsy shows:
  • Parakeratinisation or less frequently orthokeratinisation
Median rhomboid glossitis --- --- Dorsum of the tongue at the junction of the anterior two thirds

and posterior third

Forms a patch of papillary atrophy in the region of the

embryological foramen caecum

Biopsy shows:
Salivary gland tumors Acinic cell carcinoma
  • 2-6.5% of all intraoral salivary gland tumors
  • Age range from 11-77 years, with a mean of 45 years
  • Male to female ratio of 1.5:1
Tumors usually

form non-descript swellings

Biopsy shows:
  • Solid sheets of epithelium with secretory material
  • Ductal differentiation in tumors
Mucoepidermoid carcinoma
  • 9.5-23% of all minor gland tumors
Low power microscopy shows low-grade tumor with both cystic and solid areas and an inflamed, fibrous stroma
Adenoid cystic carcinoma
  • 42.5% of minor gland tumors
Predominantly solid variant shows peri- and intraneural invasion
Epithelial-myoepithelial

carcinoma

--- --- --- ---
Clear cell carcinoma,

NOS

--- --- ---
Basal cell

adenocarcinoma

Rare in minor glands Asymptomatic, smooth or lobulated sub-mucosal masses Microscopically similar to basal

cell adenocarcinomas of the major gland

Cystadenocarcinoma 32% developed in the minor glands Slow growing and painless but

some palatal tumors may erode the

underlying bone causing sinonasal complex

---
Salivary duct carcinoma
  • Rare in minor salivary glands
  • Age range was 23-80 years (mean 56 years)
Tumors formed painless swellings but many in the palate can be painful and ulcerated or fungated with metastases to regional lymph nodes The range of

microscopical appearances is similar

to that seen in the major glands

Salivary gland adenomas Pleomorphic adenoma 40-70% of minor gland tumors Painless, slow growing, submucosal masses, but when

traumatized may bleed or ulcerate

Biopsy shows cellular, and hyaline or plasmacytoid cell
Myoepithelioma 42% of minor gland tumors --- ---
Basal cell adenoma 20% of minor gland tumors --- They are histologically

similar to those in major glands.

Cystadenoma 7% of benign minor gland tumors --- ---
Kaposi sarcoma --- Biopsy of all 4 types show:
Lymphangioma ---
  • Appear mostly in the head and neck area but may be found in any other part of the body
Tongue
  • Circumscribed painless swelling
  • Soft and fluctuant on palpation
  • Irregular nodularity of the dorsum of the tongue
Biopsy shows:
Ectomesenchymal chondromyxoid

tumour of the anterior tongue

---
  • Age range varies from 9-78 years
  • No distinct sex predilection.
--- Asymptomatic, slow growing solitary nodule in the anterior dorsal tongue Biopsy shows:
Focal oral mucinosis (FOM) ---
  • The lesion affects all ages
  • Rare in children
  • There is no distinct sex predilection.
Asymptomatic fibrous or cystic-like lesion Histopathology is characterized by:
  • Mucinous material shows alcianophilia at pH 2.5
Congenital granular cell epuli ---
  • Affects newborns
  • Females are affected ten times more often than males
Solitary, somewhat pedunculated fibroma-like lesion attached to the alveolar

ridge near the midline

Hematolymphoid tumors Non-Hodgkin lymphoma Second most common cancer of the oral cavity NHL of the lip presents with: Biopsy shows:
  • Large cells with predominantly round nuclei and membrane-bound nucleoli, consistent with centroblastic morphology.
  • Predominantly medium-sized cells with abundant pale cytoplasm.
  • Large cells with round or multilobated nuclei
Langerhans cell histiocytosis ---
  • Jaw bone
  • Intraoral soft tissues
  • Gingiva

and

Common oral symptoms

include:

Biopsy shows ovoid Langerhans cells

with deeply grooved nuclei, thin nuclear membranes and abundant eosinophilic cytoplasm

Hodgkin lymphoma --- Most patients present with localized disease (stage I/II), with ---
Extramedullary myeloid

sarcoma

--- Isolated tumor-forming intraoral mass Biopsy shows an Indian-file pattern of infiltration
Follicular dendritic cell

sarcoma / tumour

  • Tumor of adulthood
  • Affects wide age range
The patients usually

present with a painless mass

Biopsy usually exhibits

borders and comprises:

  • Storiform arrays or
  • Diffuse sheets of spindly to ovoid tumor cells sprinkled with small lymphocytes
Mucosal malignant melanoma ---
  • 0.5% of oral malignancies
  • Incidence 0.02 per 100,000
80% arise:

Others:

  • Floor of mouth
  • Biopsy:
  • S100 positive
  • Negative for cytokeratins
  • More specific markers include:
  • HMB45,
  • Melan-A or anti-tyrosinase